Replies to post #61604 on Biotech Values

[DewDiligence]

>Crestor – By chance would you know what the economics are for Shionogi (Is it a straight royalty/capped/etc.)?<

It’s unusual for Big Pharma to allow this kind of information to be disclosed, so the chances are it hasn’t been.

>My interest in Shionogi is for another drug not yet approved<

Pirfenidone, perchance? :-)

[DewDiligence]

1Q08 Crestor sales: $772M, +16%. Not bad, but it still has a long way to go to become the biggest-selling drug of all time.

http://www.astrazeneca.com/sites/7/imagebank/typearticleparam511817/astrazeneca-q1-results-2008-narrative.pdf

Crestor’s share of US Rx’s in the statin group was 8.5% in March 2008.